| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cardiotoxin Analog (CTX) IV 6-12 does not have a well-defined specific molecular target. The parent cardiotoxin (CTX IV) is a three-finger toxin that binds to cell membranes and induces cytolytic effects through interactions with phospholipids and membrane proteins. Cardiotoxins are known to interact with cell membranes, causing membrane depolarization, disruption of membrane integrity, and cell lysis. The 6-12 fragment represents a portion of the larger toxin and may retain some membrane-interacting properties. The peptide has a three-finger ring structure similar to neurotoxins and muscarinic toxins. This fragment is used to investigate the minimal structural determinants required for cytolytic activity.
|
|---|---|
| ln Vitro |
In vitro, Cardiotoxin Analog (CTX) IV 6-12 has cytolytic effects on many cells. The parent cardiotoxin IV, from which this fragment is derived, is a unique snake venom cardiotoxin with membrane-disrupting properties. The 6-12 peptide fragment is used to study the structural and functional properties of cardiotoxins and their interactions with cell membranes. As a synthetic peptide, CTX IV 6-12 enables the study of complex biochemical processes without the variability associated with crude venom extracts. The exact cytolytic potency of the fragment compared to the full-length toxin may be reduced, but it retains utility as a research tool.
|
| ln Vivo |
In vivo data for Cardiotoxin Analog (CTX) IV 6-12 are limited. The parent cardiotoxins from snake venom are known to cause cardiotoxicity, cytolysis, and other effects when administered systemically. However, the 6-12 peptide fragment is primarily used as a research tool in in vitro studies. No specific in vivo studies have been reported for this fragment. The compound is intended for research use only and is not for human therapeutic applications.
|
| Enzyme Assay |
In vitro assays for Cardiotoxin Analog (CTX) IV 6-12 involve assessment of cytolytic activity against various cell types. Cells (e.g., erythrocytes, myocytes, or cancer cell lines) are cultured in appropriate medium and seeded in 96-well plates. The peptide is dissolved in PBS or buffer and added to cells at concentrations ranging from 0.1-100 microM. Cells are incubated at 37degC for 1-24 hours. Cytolytic activity is assessed by measuring LDH release, hemoglobin release (for erythrocyte lysis assays), or cell viability using MTT or CellTiter-Glo assays. For membrane interaction studies, the peptide is incubated with liposomes or model membranes, and changes in membrane integrity are monitored by fluorescence spectroscopy using calcein release or dye leakage assays. The cytolytic potency is determined from dose-response curves.
|
| Cell Assay |
Cellular assays for Cardiotoxin Analog (CTX) IV 6-12 are performed using various cell lines to assess cytotoxicity and membrane-disrupting activity. Cell lines such as HeLa, HEK-293, or primary myocytes are cultured in appropriate medium supplemented with FBS and antibiotics. Cells are seeded in 96-well plates at 5 × 103-2 × 10⁴ cells/well and allowed to attach overnight. Cells are treated with the peptide (0.1-100 microM) for 1-48 hours. Cell viability is measured using the MTT assay. Apoptosis is assessed by Annexin V/PI staining and flow cytometry. Membrane integrity is evaluated by LDH release or propidium iodide uptake. The cytolytic activity of CTX IV 6-12 is compared to the full-length cardiotoxin to determine the contribution of the 6-12 region to the overall activity.
|
| Animal Protocol |
In vivo animal studies for Cardiotoxin Analog (CTX) IV 6-12 have not been extensively reported. The parent cardiotoxins from snake venom are typically studied in rodent models to evaluate toxicity and pharmacological effects. In such studies, cardiotoxins are administered intravenously or intraperitoneally, and animals are monitored for cardiotoxic effects including arrhythmias, hypotension, and respiratory distress. However, specific protocols for the 6-12 peptide fragment have not been published. The peptide is intended for in vitro research use only. Researchers should consult the primary literature for the most current information.
|
| ADME/Pharmacokinetics |
Cardiotoxin Analog (CTX) IV 6-12 (CAS#: 115722-23-1) has molecular formula C4₈H₇0N10O₇ and molecular weight 899.13. The peptide sequence is Leu-Ile-Pro-Pro-Phe-Trp-Lys-NH2. It is a synthetic peptide fragment derived from Cardiotoxin Analog IV, a snake venom cardiotoxin from Naja naja atra. The peptide has a three-finger ring structure similar to neurotoxins and muscarinic toxins. It is used in research to study the structure-activity relationships of cardiotoxins and their cytolytic effects on cells. The compound is supplied for research use only and is not for human therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological information for Cardiotoxin Analog (CTX) IV 6-12 is limited as the compound is a research peptide. The parent cardiotoxins from snake venom are potent cytolytic toxins that cause cell lysis, cardiotoxicity, and other effects. The 6-12 peptide fragment may retain some cytolytic activity but is considerably less potent than the full-length toxin. The compound should be handled with standard laboratory precautions including the use of personal protective equipment and working in a well-ventilated area. Avoid inhalation, ingestion, and skin contact. The peptide should be stored at -20degC and disposed of according to institutional guidelines for biological and chemical waste.
|
| References | |
| Additional Infomation |
Cardiotoxin Analog (CTX) IV 6-12 (CAS#: 115722-23-1) is a synthetic peptide fragment (residues 6-12) of Cardiotoxin Analog IV, a unique snake venom cardiotoxin isolated from the Taiwan cobra (Naja naja atra). The peptide sequence is Leu-Ile-Pro-Pro-Phe-Trp-Lys-NH2. Cardiotoxins belong to the three-finger toxin family and have cytolytic effects on many cells, including myocytes, erythrocytes, and cancer cells. CTX IV 6-12 is used as a research tool to investigate the structural determinants of cardiotoxin activity and to study membrane interactions without the complexity of crude venom extracts. The compound is supplied for research use only and is not approved for therapeutic use. As of the current date, CTX IV 6-12 remains a preclinical research peptide.
|
| Molecular Formula |
C48H70N10O7
|
|---|---|
| Molecular Weight |
899.1322
|
| Exact Mass |
898.543
|
| CAS # |
115722-23-1
|
| Related CAS # |
Cardiotoxin Analog (CTX) IV (6-12) (TFA);2918768-05-3
|
| PubChem CID |
3087693
|
| Appearance |
White to off-white solid powder
|
| LogP |
7.695
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
65
|
| Complexity |
1630
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](CC(C)C)N
|
| InChi Key |
IVORLIHJCUSAQL-USNVFINLSA-N
|
| InChi Code |
InChI=1S/C48H70N10O7/c1-5-30(4)41(56-43(60)34(50)25-29(2)3)48(65)58-24-14-21-40(58)47(64)57-23-13-20-39(57)46(63)55-37(26-31-15-7-6-8-16-31)44(61)54-38(27-32-28-52-35-18-10-9-17-33(32)35)45(62)53-36(42(51)59)19-11-12-22-49/h6-10,15-18,28-30,34,36-41,52H,5,11-14,19-27,49-50H2,1-4H3,(H2,51,59)(H,53,62)(H,54,61)(H,55,63)(H,56,60)/t30-,34-,36-,37-,38-,39-,40-,41-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-1-[(2S,3S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]-N-[(2S)-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~111.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1122 mL | 5.5609 mL | 11.1219 mL | |
| 5 mM | 0.2224 mL | 1.1122 mL | 2.2244 mL | |
| 10 mM | 0.1112 mL | 0.5561 mL | 1.1122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
